Mineralys Therapeutics (MLYS) Profit After Tax (2022 - 2026)
Mineralys Therapeutics (MLYS) reported Profit After Tax of -$39.3 million for Q1 2026, up 6.9% on a YoY basis from -$36.8 million in Q1 2025, and down 21.74% sequentially from -$32.3 million in Q4 2025.
Mineralys Therapeutics (MLYS) Profit After Tax (2022 - 2026) Analysis & Trends
Mineralys Therapeutics (MLYS) has 5 years of Profit After Tax data on file, last reported at -$39.3 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 6.9% year-over-year to -$39.3 million; the trailing twelve-month figure through Mar 2026 stood at -$151.8 million (up 19.48% YoY), and the FY2025 full-year result was -$154.7 million, up 13.0% from the prior year.
- Profit After Tax retreated to -$39.3 million in Q1 2026, from -$32.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$6.5 million in Q2 2022 to a low of -$56.3 million in Q3 2024.
- A 5-year average of -$27.9 million and a median of -$31.5 million in 2024 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax slumped 240.82% in 2023 and jumped 34.45% in 2025, its largest moves.
- Tracing MLYS's Profit After Tax over 5 years: stood at -$9.1 million in 2022, then slumped by 168.81% to -$24.4 million in 2023, then plunged by 100.69% to -$48.9 million in 2024, then surged by 34.04% to -$32.3 million in 2025, then slipped by 21.74% to -$39.3 million in 2026.
- Business Quant data shows MLYS's Profit After Tax at -$39.3 million in Q1 2026, -$32.3 million in Q4 2025, and -$36.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - | -39.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.30 Mn |
| Dec 31, 2025 | -32.28 Mn |
| Sep 30, 2025 | -36.93 Mn |
| Jun 30, 2025 | -43.27 Mn |
| Mar 31, 2025 | -42.21 Mn |
| Dec 31, 2024 | -48.95 Mn |
| Sep 30, 2024 | -56.34 Mn |
| Jun 30, 2024 | -41.01 Mn |
| Mar 31, 2024 | -31.51 Mn |
| Dec 31, 2023 | -24.39 Mn |
| Sep 30, 2023 | -22.76 Mn |
| Jun 30, 2023 | -12.14 Mn |
| Mar 31, 2023 | -12.61 Mn |
| Dec 31, 2022 | -9.07 Mn |
| Sep 30, 2022 | -6.68 Mn |
| Jun 30, 2022 | -6.48 Mn |
| Mar 31, 2022 | -7.57 Mn |